Clinical Trial

Intermittent Preventive Treatment of Malaria in School-age Children to Decrease Community Transmission

Study acronym: CRITICal
Not Yet Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
The CRITICal study aims to estimate the effectiveness of intermittent preventive treatment in school children (IPTsc) with dihydroartemisinin-piperaquine (DP) for reducing community level malaria burden. Given that school-aged children are the primary drivers of transmission, the study hypothesis is that IPTsc will reduce this infectious reservoir and thus the burden of malaria in persons of all ages in surrounding communities.
Protocol Amendment History 2 changes
notable Primary completion pushed: 2029-05-31 -> 2029-08-31 2026-05-08
minor Completion pushed: 2029-05-31 -> 2029-08-31 2026-05-08
Trial Details
NCT Number NCT07246525
Lead Sponsor University of California, San Francisco
Collaborators: National Institute of Allergy and Infectious Diseases (NIAID), Infectious Diseases Research Collaboration, Uganda, Ministry of Health, Uganda
Conditions Malaria
Enrollment 4,800 participants
Start Date 2026-08-01
Primary Completion 2029-08-31 (estimated)
Study Completion 2029-08-31 (estimated)
Updated on ClinicalTrials.gov 2026-05-07